Business
20/20 BioLabs Reports First Quarter 2026 Financial Results and Recent Operational Progress
State-Funded Firefighter Cancer Screening Programs Expected to Drive Meaningful Revenue Growth Beginning in Q2 2026 $5.0 Million Private Placement Strengthens Cash Position to $4.2 Million as of March 31, 2026 Recent Strategic Wins Include Evexia Diagnostics Distribution Agreement, ROKIT Healthcare CKD License, and Commercial Launch of OneTest™ for Longevity GAITHERSBURG, Md., May 20, 2026 (GLOBE NEWSWIRE) -- 20/20 BioLabs, Inc. (Nasdaq: AIDX) (“20/20” or the “Company”), an early market entrant
About this update from 20/20 Biolabs, Inc.
[{"type":"image","alt":"20/20 Biolabs Inc.","displaySize":"","headline":null,"caption":"20/20 Biolabs Inc.","className":"","disableSlideshowImg":false,"size":{"original":{"width":244,"height":159,"url":"https://media.zenfs.com/en/globenewswire.com/d2abb3d4c13adceb39a31a2c97271190"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/vj6D.5WcDNqHtzfFPjjYPA--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTI3NA--/https://media.zenfs.com/en/globenewswire.com/d2abb3d4c13adceb39a31a2c97271190","width":244,"height":159},"resize_sm":{"url":"https://s.yimg.com/ny/api/res/1.2/vj6D.5WcDNqHtzfFPjjYPA--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTI3NA--/https://media.zenfs.com/en/globenewswire.com/d2abb3d4c13adceb39a31a2c97271190","width":244,"height":159}},"lazy":false},{"type":"text","content":"State-Funded Firefighter Cancer Screening Programs Expected to Drive Meaningful Revenue Growth Beginning in Q2 2026","length":115,"tagName":"p"},{"type":"text","content":"$5.0 Million Private Placement Strengthens Cash Position to $4.2 Million as of March 31, 2026","length":93,"tagName":"p"},{"type":"text","content":"Recent Strategic Wins Include Evexia Diagnostics Distribution Agreement, ROKIT Healthcare CKD License, and Commercial Launch of OneTest™ for Longevity","length":150,"tagName":"p"},{"type":"text","content":"GAITHERSBURG, Md., May 20, 2026 (GLOBE NEWSWIRE) -- 20/20 BioLabs, Inc. (Nasdaq: AIDX) (“20/20” or the “Company”), an early market entrant in AI powered laboratory-based blood tests for the early detection and prevention of cancers and chronic diseases, reported its financial and operational results for the first quarter ended March 31, 2026.","length":344,"tagName":"p"},{"type":"text","content":"First Quarter & Subsequent 2026 Operational Highlights","length":58,"tagName":"p"},{"type":"list","items":[{"val":[{"type":"text","content":"Revenue of $0.4 million for Q1 2026, as compared to $0.6 million for Q1 2025. The decline was primarily due to the timing of orders from several larger customers in Q1 2026 that have ordered, or are expected to order, in Q2 or Q3 of 2026.","length":238,"tagName":"p"}]},{"val":[{"type":"text","content":"Q2 revenue is expected to benefit from Maryland fire departments seeking the Company’s OneTest™ Multi-Cancer Early Detection (“MCED”) blood test through Maryland’s state-funded firefighter cancer screening grant program.","length":220,"tagName":"p"}]}...